Skip to Main Content

Paper Details

Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.
Cancer Cell
41
2014
3q26, TP53INP1, cancer, cancer lineages, cisplatin, epithelial cancers, hsa, hsa-miR-569, miR569, ovarian and breast cancer, ovarian and breast cancers, patients
Author NameAffiliation
Rajesha RupaimooleThe University of Texas MD Anderson Cancer Center
Yiling LuThe University of Texas MD Anderson Cancer Center
Chad V PecotThe University of Texas MD Anderson Cancer Center
Vessela N KristensenInstitute for Cancer Research, Oslo University Hospital, the Norwegian Radium Hospital, Norway The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo
Prahlad T RamThe University of Texas MD Anderson Cancer Center
Wenbin LiuThe University of Texas MD Anderson Cancer Center
Anne-Lise B??rresen-DaleInstitute for Cancer Research, Oslo University Hospital, the Norwegian Radium Hospital, Norway The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo
Anne-Lise B??rresen-DaleInstitute for Cancer Research, Oslo University Hospital, the Norwegian Radium Hospital, Norway The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo
Joe W GrayOregon Health and Science University
Joe W GrayOregon Health and Science University
Elsa R FloresThe University of Texas MD Anderson Cancer Center
Anil K SoodThe University of Texas MD Anderson Cancer Center, USA Center for RNAi and Non-Coding RNA
Gordon B MillsThe University of Texas MD Anderson Cancer Center
Gordon B MillsThe University of Texas MD Anderson Cancer Center
  • 1 - 14

Datasets

Release 1.2